University of Arizona Cancer Center researchers were awarded a $1.5 million grant from the National Cancer Institute to deliver an intensive, multidisciplinary cancer prevention and control research training program for undergraduate and graduate students.
Adcomm says Intercept’s rare liver disease drug should not get full approval
An FDA advisory committee recommended against full approval for Alfasigma and Intercept Pharmaceuticals’ rare liver disease drug Ocaliva by a 13-1 vote, concluding that confirmatory
September 14, 2024